aminolevulinic acid has been researched along with Minimal Disease, Residual in 41 studies
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Introducing 5-aminolevulinic acid-photodynamic diagnosis into transurethral resection reduces residual bladder cancer and improves the cumulative intravesical recurrence-free survival in patients with non-muscle-invasive bladder cancer, indicating its possible therapeutic benefits." | 8.12 | Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer. ( Harada, S; Honda, T; Kani, N; Kato, T; Matsuoka, Y; Okazoe, H; Sugimoto, M; Taoka, R; Tohi, Y; Tsunemori, H; Ueda, N; Yamasaki, M, 2022) |
| "Our observations suggest that 5-aminolevulinic acid-induced porphyrin fluorescence may label malignant gliomas safely and accurately enough to enhance the completeness of tumor removal." | 7.70 | Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. ( Fritsch, C; Goetz, AE; Goetz, C; Kiefmann, R; Reulen, HJ; Stepp, H; Stocker, S; Stummer, W; Wagner, S, 1998) |
| "Significant reduction in the number of residual tumours was detected in 59% (p = 0." | 6.71 | [Clinical significance of macroscopic 5-aminolevulinic acid (ALA)-inducer fluorescence in transurethral resection of non-invasive bladder cancer]. ( Al-Shukri, S; Danil'chenko, DI; Koenig, F; Loening, SA; Riedl, K; Schnorr, D; Waldman, A, 2003) |
| "Evaluation of residual tumor rate and recurrence free survival were defined as the two primary study endpoints." | 6.71 | [Reducing the risk of superficial bladder cancer recurrence with 5-aminolevulinic acid-induced fluorescence diagnosis. Results of a 5-year study]. ( Filbeck, T; Knuechel, R; Pichlmeier, U; Rössler, W; Wieland, WF, 2003) |
| "Residual tumor was evaluated in the 2 groups by repeat transurethral resection 10 to 14 days later." | 6.70 | Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. ( Eisenberger, F; Hofstetter, A; Jocham, D; Kriegmair, M; Rassweiler, J; Rothenberger, KH; Stenzl, A; Tauber, R; Zaak, D, 2002) |
| "The risk of residual tumor after transurethral resection of transitional cell carcinoma is significantly decreased by 5-aminolevulinic acid fluorescence endoscopy." | 6.70 | Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. ( Eisenberger, F; Hofstetter, A; Jocham, D; Kriegmair, M; Rassweiler, J; Rothenberger, KH; Stenzl, A; Tauber, R; Zaak, D, 2002) |
| "5-aminolevulinic acid is a protoporphyrin IX precursor used for photodynamic diagnosis." | 5.72 | Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer. ( Harada, S; Honda, T; Kani, N; Kato, T; Matsuoka, Y; Okazoe, H; Sugimoto, M; Taoka, R; Tohi, Y; Tsunemori, H; Ueda, N; Yamasaki, M, 2022) |
| "Multiple myeloma is the cancer of plasma cells." | 5.51 | Flow Cytometry-Based Photodynamic Diagnosis with 5-Aminolevulinic Acid for the Detection of Minimal Residual Disease in Multiple Myeloma. ( Fujimaki, S; Fujiwara, M; Fujiwara, T; Fukuhara, N; Harigae, H; Ito, T; Iwaki, K; Onishi, Y; Ono, K; Saito, K; Sasaki, K; Suzuki, C; Tamura, H; Tanaka, T; Yokoyama, H, 2019) |
| "5-Aminolevulinic acid (ALA) is a natural compound in the heme biosynthesis pathway." | 5.51 | Flow Cytometry-Based Photodynamic Diagnosis with 5-Aminolevulinic Acid for the Detection of Minimal Residual Disease in Multiple Myeloma. ( Fujimaki, S; Fujiwara, M; Fujiwara, T; Fukuhara, N; Harigae, H; Ito, T; Iwaki, K; Onishi, Y; Ono, K; Saito, K; Sasaki, K; Suzuki, C; Tamura, H; Tanaka, T; Yokoyama, H, 2019) |
| "5-Aminolevulinic acid (5-ALA) fluorescence can maximize perirolandic glioblastoma (GBM) resection with low rates of postoperative sequelae." | 5.22 | Functional outcomes, extent of resection, and bright/vague fluorescence interface in resection of glioblastomas involving the motor pathways assisted by 5-ALA. ( Bonaudo, C; Campagnaro, L; Carrai, R; Ciccarino, P; Dardo, M; Della Puppa, A; Esposito, A; Fainardi, E; Muscas, G; Orlandini, S, 2022) |
| "Controversy exists regarding the therapeutic benefit and cost effectiveness of photodynamic diagnosis (PDD) with 5-aminolevulinic acid (5-ALA) or hexyl aminolevulinate (HAL) in addition to white-light cystoscopy (WLC) in the management of non-muscle-invasive bladder cancer (NMIBC)." | 4.89 | Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. ( Babjuk, M; Catto, JW; Jichlinski, P; Rink, M; Shariat, SF; Stenzl, A; Stepp, H; Witjes, JA; Zaak, D, 2013) |
| "The clinical benefit of photodynamic diagnosis (PDD) with 5-aminolevulinic acid or hexaminolevulinate in addition to white-light cystoscopy (WLC) in bladder cancer has been discussed controversially." | 4.86 | Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. ( Jacqmin, D; Jichlinski, P; Jocham, D; Kausch, I; Montorsi, F; Sommerauer, M; Stenzl, A; Vonthein, R; Ziegler, A, 2010) |
| "Introducing 5-aminolevulinic acid-photodynamic diagnosis into transurethral resection reduces residual bladder cancer and improves the cumulative intravesical recurrence-free survival in patients with non-muscle-invasive bladder cancer, indicating its possible therapeutic benefits." | 4.12 | Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer. ( Harada, S; Honda, T; Kani, N; Kato, T; Matsuoka, Y; Okazoe, H; Sugimoto, M; Taoka, R; Tohi, Y; Tsunemori, H; Ueda, N; Yamasaki, M, 2022) |
| "Our observations suggest that 5-aminolevulinic acid-induced porphyrin fluorescence may label malignant gliomas safely and accurately enough to enhance the completeness of tumor removal." | 3.70 | Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. ( Fritsch, C; Goetz, AE; Goetz, C; Kiefmann, R; Reulen, HJ; Stepp, H; Stocker, S; Stummer, W; Wagner, S, 1998) |
| "Residual tumor was found in 15 (75%) AK and in 4 (66." | 2.73 | Fractionated illumination improves the outcome in the treatment of precancerous lesions with photodynamic therapy. ( Mirić, L; Persin, A; Puizina-Ivić, N; Vanjaka-Rogosić, L; Zorc, H, 2008) |
| "Significant reduction in the number of residual tumours was detected in 59% (p = 0." | 2.71 | [Clinical significance of macroscopic 5-aminolevulinic acid (ALA)-inducer fluorescence in transurethral resection of non-invasive bladder cancer]. ( Al-Shukri, S; Danil'chenko, DI; Koenig, F; Loening, SA; Riedl, K; Schnorr, D; Waldman, A, 2003) |
| "Evaluation of residual tumor rate and recurrence free survival were defined as the two primary study endpoints." | 2.71 | [Reducing the risk of superficial bladder cancer recurrence with 5-aminolevulinic acid-induced fluorescence diagnosis. Results of a 5-year study]. ( Filbeck, T; Knuechel, R; Pichlmeier, U; Rössler, W; Wieland, WF, 2003) |
| "Residual tumor was evaluated in the 2 groups by repeat transurethral resection 10 to 14 days later." | 2.70 | Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. ( Eisenberger, F; Hofstetter, A; Jocham, D; Kriegmair, M; Rassweiler, J; Rothenberger, KH; Stenzl, A; Tauber, R; Zaak, D, 2002) |
| "The risk of residual tumor after transurethral resection of transitional cell carcinoma is significantly decreased by 5-aminolevulinic acid fluorescence endoscopy." | 2.70 | Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. ( Eisenberger, F; Hofstetter, A; Jocham, D; Kriegmair, M; Rassweiler, J; Rothenberger, KH; Stenzl, A; Tauber, R; Zaak, D, 2002) |
| "Non-muscle-invasive bladder cancer (NMIBC) is associated with a high recurrence risk, partly because of the persistence of lesions following transurethral resection of bladder tumour (TURBT) due to the presence of multiple lesions and the difficulty in identifying the exact extent and location of tumours using standard white-light cystoscopy (WLC)." | 2.50 | Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations. ( Babjuk, M; Gontero, P; Jacqmin, D; Karl, A; Kruck, S; Mariappan, P; Palou Redorta, J; Stenzl, A; van Velthoven, R; Witjes, JA; Zaak, D, 2014) |
| "Residual tumour was significantly less often found after PDD (odds ratio: 0." | 2.46 | Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. ( Jacqmin, D; Jichlinski, P; Jocham, D; Kausch, I; Montorsi, F; Sommerauer, M; Stenzl, A; Vonthein, R; Ziegler, A, 2010) |
| "5-aminolevulinic acid is a protoporphyrin IX precursor used for photodynamic diagnosis." | 1.72 | Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer. ( Harada, S; Honda, T; Kani, N; Kato, T; Matsuoka, Y; Okazoe, H; Sugimoto, M; Taoka, R; Tohi, Y; Tsunemori, H; Ueda, N; Yamasaki, M, 2022) |
| "Sensitivity and specificity were calculated for Gd-DTPA MRI, PWI, met-PET, and 5-ALA according to the histology of specimen." | 1.51 | Diagnostic accuracy of intraoperative perfusion-weighted MRI and 5-aminolevulinic acid in relation to contrast-enhanced intraoperative MRI and ( Beer, AJ; Coburger, J; Eberhardt, N; König, R; Pala, A; Reske, SN; Scheuerle, A; Schmitz, B; Wirtz, CR, 2019) |
| "5-Aminolevulinic acid (ALA) is a natural compound in the heme biosynthesis pathway." | 1.51 | Flow Cytometry-Based Photodynamic Diagnosis with 5-Aminolevulinic Acid for the Detection of Minimal Residual Disease in Multiple Myeloma. ( Fujimaki, S; Fujiwara, M; Fujiwara, T; Fukuhara, N; Harigae, H; Ito, T; Iwaki, K; Onishi, Y; Ono, K; Saito, K; Sasaki, K; Suzuki, C; Tamura, H; Tanaka, T; Yokoyama, H, 2019) |
| "Multiple myeloma is the cancer of plasma cells." | 1.51 | Flow Cytometry-Based Photodynamic Diagnosis with 5-Aminolevulinic Acid for the Detection of Minimal Residual Disease in Multiple Myeloma. ( Fujimaki, S; Fujiwara, M; Fujiwara, T; Fukuhara, N; Harigae, H; Ito, T; Iwaki, K; Onishi, Y; Ono, K; Saito, K; Sasaki, K; Suzuki, C; Tamura, H; Tanaka, T; Yokoyama, H, 2019) |
| "To evaluate the residual tumor rate, the bladder was inspected after its removal and normal appearing mucosa sampled for histologic analysis." | 1.46 | Diagnostic Accuracy of Hexaminolevulinate in a Cohort of Patients Undergoing Radical Cystectomy. ( Alba, S; Buscarini, M; Carrieri, G; Cormio, L; Di Stasi, S; Gallone, MF; Minafra, P; Pagliarulo, V; Petitti, T, 2017) |
| "Sensitivity and specificity to detect residual tumor tissue were 75% and 100%, respectively, for iMRI and 70% and 100% for 5-ALA fluorescence." | 1.42 | Combination of Intraoperative Magnetic Resonance Imaging and Intraoperative Fluorescence to Enhance the Resection of Contrast Enhancing Gliomas. ( Duetzmann, S; Forster, MT; Franz, K; Gessler, F; Hattingen, E; Mittelbronn, M; Seifert, V; Senft, C, 2015) |
| "In liver metastasis from colorectal cancer cases with serosa invasion, 18 patients (85." | 1.40 | Fluorescence detection of malignant liver tumors using 5-aminolevulinic acid-mediated photodynamic diagnosis: principles, technique, and clinical experience. ( Hayashi, M; Hirokawa, F; Inoue, Y; Komeda, K; Tanaka, R; Uchiyama, K, 2014) |
| "5-ALA fluorescence was detected in all hepatocellular carcinoma cases with serosa invasion." | 1.40 | Fluorescence detection of malignant liver tumors using 5-aminolevulinic acid-mediated photodynamic diagnosis: principles, technique, and clinical experience. ( Hayashi, M; Hirokawa, F; Inoue, Y; Komeda, K; Tanaka, R; Uchiyama, K, 2014) |
| "Analysis of residual tumor volumes, total resections and neurological outcomes demonstrate that iMRI may be significantly superior to 5-ALA and white-light surgery for glioblastomas at comparable peri- and postoperative morbidities." | 1.40 | Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery. ( Bisdas, S; Ebner, FH; Ernemann, U; Honegger, J; Naegele, T; Roder, C; Tatagiba, M, 2014) |
| "Mean residual tumor volume (range) after iMRI-assisted surgery [0." | 1.40 | Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery. ( Bisdas, S; Ebner, FH; Ernemann, U; Honegger, J; Naegele, T; Roder, C; Tatagiba, M, 2014) |
| "Perianal squamous cell carcinoma in situ (SCCIS) is a relatively rare intraepidermal neoplasm that has the potential to progress to invasive squamous cell carcinoma." | 1.40 | Combination therapy for perianal squamous cell carcinoma in situ with imiquimod and photodynamic therapy. ( Bontumasi, NM; Hurst, EA; Sheinbein, D, 2014) |
| "5-aminolevulinic acid (5-ALA) is a pro-drug that leads to accumulation of fluorescent protoporphyrins in malignant gliomas." | 1.38 | Fluorescence-guided resection of gliomas. ( Cortnum, S; Laursen, RJ, 2012) |
| "We compared resection completeness and residual tumor, determined by histopathology, after white light resection (WLR) using an operating microscope versus additional fluorescence guided resection (FGR)." | 1.32 | Increased brain tumor resection using fluorescence image guidance in a preclinical model. ( Bilbao, JM; Bogaards, A; Collens, SP; Giles, A; Lilge, LD; Lin, A; Muller, PJ; Varma, A; Wilson, BC; Yang, VX, 2004) |
| "This was first shown for cancer of the bladder." | 1.31 | [Fluorescent endoscopy superior to white light endoscopy. Detecting cancers of the urinary bladder earlier]. ( Zaak, D, 2002) |
| "Following transurethral resection of bladder cancer, the fate of patients is clearly related to the presence or absence of precancerous or malignant lesions in the remaining mucosa." | 1.29 | [Photodynamic diagnosis of urothelial neoplasms after intravesicular instillation of 5-aminolevulinic acid]. ( Baumgartner, R; Ehsan, A; Hofstädter, F; Hofstetter, A; Knüchel, R; Kriegmair, M; Lumper, W; Steinbach, P, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.88) | 18.2507 |
| 2000's | 12 (29.27) | 29.6817 |
| 2010's | 23 (56.10) | 24.3611 |
| 2020's | 4 (9.76) | 2.80 |
| Authors | Studies |
|---|---|
| Taoka, R | 1 |
| Matsuoka, Y | 1 |
| Yamasaki, M | 1 |
| Kani, N | 1 |
| Honda, T | 1 |
| Harada, S | 1 |
| Tohi, Y | 1 |
| Kato, T | 1 |
| Okazoe, H | 1 |
| Tsunemori, H | 1 |
| Ueda, N | 1 |
| Sugimoto, M | 1 |
| Muscas, G | 1 |
| Orlandini, S | 1 |
| Bonaudo, C | 1 |
| Dardo, M | 1 |
| Esposito, A | 1 |
| Campagnaro, L | 1 |
| Carrai, R | 1 |
| Fainardi, E | 1 |
| Ciccarino, P | 1 |
| Della Puppa, A | 1 |
| Zhao, H | 3 |
| Peng, P | 3 |
| Luo, Z | 3 |
| Liu, H | 3 |
| Sun, J | 3 |
| Wang, X | 3 |
| Jia, Q | 3 |
| Yang, Z | 3 |
| Ross, JL | 1 |
| Cooper, LAD | 1 |
| Kong, J | 1 |
| Gutman, D | 1 |
| Williams, M | 1 |
| Tucker-Burden, C | 1 |
| McCrary, MR | 1 |
| Bouras, A | 1 |
| Kaluzova, M | 1 |
| Dunn, WD | 1 |
| Duong, D | 1 |
| Hadjipanayis, CG | 1 |
| Brat, DJ | 1 |
| Pala, A | 1 |
| Reske, SN | 1 |
| Eberhardt, N | 1 |
| Scheuerle, A | 1 |
| König, R | 2 |
| Schmitz, B | 1 |
| Beer, AJ | 1 |
| Wirtz, CR | 2 |
| Coburger, J | 2 |
| Michael, AP | 1 |
| Watson, VL | 1 |
| Ryan, D | 1 |
| Delfino, KR | 1 |
| Bekker, SV | 1 |
| Cozzens, JW | 1 |
| Langen, KJ | 1 |
| Floeth, FW | 1 |
| Galldiks, N | 1 |
| Rink, M | 1 |
| Babjuk, M | 3 |
| Catto, JW | 1 |
| Jichlinski, P | 2 |
| Shariat, SF | 1 |
| Stenzl, A | 5 |
| Stepp, H | 3 |
| Zaak, D | 6 |
| Witjes, JA | 3 |
| Apalla, Z | 1 |
| Lallas, A | 1 |
| Tzellos, T | 1 |
| Sidiropoulos, T | 1 |
| Lefaki, I | 1 |
| Trakatelli, M | 1 |
| Sotiriou, E | 1 |
| Lazaridou, E | 1 |
| Evangelou, G | 1 |
| Patsatsi, A | 1 |
| Kyrgidis, A | 1 |
| Stratigos, A | 1 |
| Zalaudek, I | 1 |
| Argenziano, G | 1 |
| Ioannides, D | 1 |
| Roder, C | 1 |
| Bisdas, S | 1 |
| Ebner, FH | 1 |
| Honegger, J | 1 |
| Naegele, T | 1 |
| Ernemann, U | 1 |
| Tatagiba, M | 1 |
| Inoue, Y | 1 |
| Tanaka, R | 1 |
| Komeda, K | 1 |
| Hirokawa, F | 1 |
| Hayashi, M | 1 |
| Uchiyama, K | 1 |
| Gontero, P | 1 |
| Jacqmin, D | 3 |
| Karl, A | 1 |
| Kruck, S | 1 |
| Mariappan, P | 1 |
| Palou Redorta, J | 1 |
| van Velthoven, R | 1 |
| Bontumasi, NM | 1 |
| Sheinbein, D | 1 |
| Hurst, EA | 1 |
| Gessler, F | 1 |
| Forster, MT | 1 |
| Duetzmann, S | 1 |
| Mittelbronn, M | 1 |
| Hattingen, E | 1 |
| Franz, K | 1 |
| Seifert, V | 1 |
| Senft, C | 1 |
| Hagel, V | 1 |
| Guyotat, J | 2 |
| Pallud, J | 1 |
| Armoiry, X | 2 |
| Pavlov, V | 1 |
| Metellus, P | 1 |
| Pagliarulo, V | 1 |
| Alba, S | 1 |
| Gallone, MF | 1 |
| Di Stasi, S | 1 |
| Cormio, L | 1 |
| Petitti, T | 1 |
| Buscarini, M | 1 |
| Minafra, P | 1 |
| Carrieri, G | 1 |
| Puizina-Ivić, N | 1 |
| Zorc, H | 1 |
| Vanjaka-Rogosić, L | 1 |
| Mirić, L | 1 |
| Persin, A | 1 |
| Tonn, JC | 2 |
| Stummer, W | 3 |
| Burger, M | 1 |
| Stief, CG | 1 |
| Wieland, WF | 2 |
| Jocham, D | 4 |
| Otto, W | 1 |
| Denzinger, S | 1 |
| Scarpa, RM | 1 |
| Cracco, CM | 1 |
| Kausch, I | 1 |
| Sommerauer, M | 1 |
| Montorsi, F | 2 |
| Ziegler, A | 1 |
| Vonthein, R | 1 |
| Redorta, JP | 1 |
| Sofras, F | 1 |
| Malmström, PU | 1 |
| Riedl, C | 1 |
| Conti, G | 1 |
| Arentsen, HC | 1 |
| Mostafid, AH | 1 |
| Roessler, K | 2 |
| Becherer, A | 1 |
| Donat, M | 1 |
| Cejna, M | 1 |
| Zachenhofer, I | 1 |
| Roberts, DW | 1 |
| Valdés, PA | 1 |
| Harris, BT | 1 |
| Hartov, A | 1 |
| Fan, X | 1 |
| Ji, S | 1 |
| Leblond, F | 1 |
| Tosteson, TD | 1 |
| Wilson, BC | 2 |
| Paulsen, KD | 1 |
| Cortnum, S | 1 |
| Laursen, RJ | 1 |
| Eyüpoglu, IY | 1 |
| Hore, N | 1 |
| Savaskan, NE | 1 |
| Grummich, P | 1 |
| Buchfelder, M | 1 |
| Ganslandt, O | 1 |
| Jacquesson, T | 1 |
| Ducray, F | 1 |
| Maucort-Boulch, D | 1 |
| Louis-Tisserand, G | 1 |
| Mbaye, M | 1 |
| Pelissou-Guyotat, I | 1 |
| Kriegmair, M | 2 |
| Rothenberger, KH | 1 |
| Rassweiler, J | 1 |
| Eisenberger, F | 1 |
| Tauber, R | 1 |
| Hofstetter, A | 2 |
| Reulen, HJ | 2 |
| Novotny, A | 1 |
| Filbeck, T | 1 |
| Pichlmeier, U | 1 |
| Knuechel, R | 1 |
| Rössler, W | 1 |
| Danil'chenko, DI | 1 |
| Koenig, F | 1 |
| Riedl, K | 1 |
| Schnorr, D | 1 |
| Waldman, A | 1 |
| Al-Shukri, S | 1 |
| Loening, SA | 1 |
| Bogaards, A | 1 |
| Varma, A | 1 |
| Collens, SP | 1 |
| Lin, A | 1 |
| Giles, A | 1 |
| Yang, VX | 1 |
| Bilbao, JM | 1 |
| Lilge, LD | 1 |
| Muller, PJ | 1 |
| Maruyama, T | 1 |
| Utsuki, S | 1 |
| Oka, H | 1 |
| Sato, S | 1 |
| Suzuki, S | 1 |
| Shimizu, S | 1 |
| Tanaka, S | 1 |
| Fujii, K | 1 |
| Baumgartner, R | 1 |
| Knüchel, R | 1 |
| Ehsan, A | 1 |
| Steinbach, P | 1 |
| Lumper, W | 1 |
| Hofstädter, F | 1 |
| Stocker, S | 1 |
| Wagner, S | 1 |
| Fritsch, C | 1 |
| Goetz, C | 1 |
| Goetz, AE | 1 |
| Kiefmann, R | 1 |
| Iwaki, K | 1 |
| Fujiwara, T | 1 |
| Ito, T | 1 |
| Suzuki, C | 1 |
| Sasaki, K | 1 |
| Ono, K | 1 |
| Saito, K | 1 |
| Fukuhara, N | 1 |
| Onishi, Y | 1 |
| Yokoyama, H | 1 |
| Fujimaki, S | 1 |
| Tanaka, T | 1 |
| Tamura, H | 1 |
| Fujiwara, M | 1 |
| Harigae, H | 1 |
| Della Pepa, GM | 1 |
| Ius, T | 1 |
| La Rocca, G | 1 |
| Gaudino, S | 1 |
| Isola, M | 1 |
| Pignotti, F | 1 |
| Rapisarda, A | 1 |
| Mazzucchi, E | 1 |
| Giordano, C | 1 |
| Dragonetti, V | 1 |
| Chiesa, S | 1 |
| Balducci, M | 1 |
| Gessi, M | 1 |
| Skrap, M | 1 |
| Olivi, A | 1 |
| Marchese, E | 1 |
| Sabatino, G | 1 |
| Millesi, M | 1 |
| Kiesel, B | 1 |
| Mischkulnig, M | 1 |
| Martínez-Moreno, M | 1 |
| Wöhrer, A | 1 |
| Wolfsberger, S | 1 |
| Knosp, E | 1 |
| Widhalm, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety Analysis and Oncological Outcomes in Endoscopic Bladder Tumor Resection With Laser Holmium Compared With Transurethral Resection: a Prospective and Randomized Study[NCT05833997] | 100 participants (Anticipated) | Interventional | 2020-12-10 | Recruiting | |||
| A Phase 1 and 2 Study of 5-aminolevulinic Acid (5-ALA) to Enhance Visualisation and Resection of Malignant Glial Tumors of the Brain[NCT01128218] | Phase 1/Phase 2 | 33 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| A Phase 1 and 2 Study of 5-aminolevulinic Acid (5-ALA) to Enhance Visualisation and Resection of Malignant Glial Tumors of the Brain[NCT00977795] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2009-09-30 | Withdrawn (stopped due to PI moving to Southern Illinois University to start new protocol) | ||
| Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker: Correlation With Preoperative MR, ALA-induced PpIX Fluorescence, and Histopathology[NCT02691923] | Phase 2 | 30 participants (Anticipated) | Interventional | 2016-03-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Dose escalation from 10mg/kg to 50mg/kg to determine optimal 5-ALA dose (NCT01128218)
Timeframe: 6 months
| Intervention | Dose Limiting Toxicity (Number) |
|---|---|
| Phase 1 Dose Level 1 (10mg/kg) | 0 |
| Phase 1 Dose Level 2 (20mg/kg) | 0 |
| Phase 1 Dose Level 3 (30mg/kg) | 0 |
| Phase 1 Dose Level 4 (40mg/kg) | 0 |
| Phase 1 Dose Level 5 (50mg/kg) | 0 |
"Under blue light, the neurosurgeon will take two small biopsies per patient from areas identified as obvious tumor (fluorescent) and areas in the wall of the resection cavity that were judged to be normal (but possibly edematous), non-eloquent brain (non-fluorescent). A neuropathologist will review all biopsy specimens, including those taken from the solid tumor. Pathologic confirmation of tumor type will be made by the study reference neuropathologist.~We assessed 5-ALA's resulting fluorescence for distinguishing tumor within the brain, where~True Positive: Fluorescence showing Tumor and Biopsy result Tumor False Positive: Fluorescence showing Tumor and Biopsy result No Tumor True Negative: No Fluorescence and Biopsy result No Tumor False Negative: No Fluorescence and Biopsy result Tumor~These values represent the characteristics of 5-ALA aka its ability to distinguish tumor from non-tumor." (NCT01128218)
Timeframe: Baseline
| Intervention | Biopsies (Number) | |||
|---|---|---|---|---|
| True Positives | True Negatives | False Positives | False Negatives | |
| Phase 2 Dose Level 1 (40mg/kg) | 14 | 6 | 0 | 8 |
"The neurosurgeon will take two small biopsies per patient from areas identified as obvious tumor and areas in the wall of the resection cavity that were judged to be normal, non-eloquent brain. A neuropathologist will review all biopsy specimens, including those taken from the solid tumor. Pathologic confirmation of tumor type will be made by the study reference neuropathologist.~We assessed 5-ALA's resulting fluorescence for distinguishing tumor within the brain, where~True Positive: Fluorescence showing Tumor and Biopsy result Tumor False Positive: Fluorescence showing Tumor and Biopsy result No Tumor True Negative: No Fluorescence and Biopsy result No Tumor False Negative: No Fluorescence and Biopsy result Tumor~These values represent the characteristics of 5-ALA aka its ability to distinguish tumor from non-tumor. From these parameters we determined sensitivity, specificity and the positive and negative predictive values." (NCT01128218)
Timeframe: Baseline
| Intervention | Percentage (Number) | |||
|---|---|---|---|---|
| Sensitivity | Specificity | Positive Predictive Value | Negative Predictive Value | |
| Phase 2 Dose Level 1 (40mg/kg) | 63.64 | 100 | 100 | 42.86 |
11 reviews available for aminolevulinic acid and Minimal Disease, Residual
| Article | Year |
|---|---|
Functional outcomes, extent of resection, and bright/vague fluorescence interface in resection of glioblastomas involving the motor pathways assisted by 5-ALA.
Topics: Aminolevulinic Acid; Brain Neoplasms; Efferent Pathways; Glioblastoma; Humans; Neoplasm, Residual; R | 2022 |
Comparison of hexaminolevulinate (HAL) -guided versus white light transurethral resection for NMIBC: A systematic review and meta-analysis of randomized controlled trials.
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Photochemot | 2023 |
Comparison of hexaminolevulinate (HAL) -guided versus white light transurethral resection for NMIBC: A systematic review and meta-analysis of randomized controlled trials.
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Photochemot | 2023 |
Comparison of hexaminolevulinate (HAL) -guided versus white light transurethral resection for NMIBC: A systematic review and meta-analysis of randomized controlled trials.
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Photochemot | 2023 |
Comparison of hexaminolevulinate (HAL) -guided versus white light transurethral resection for NMIBC: A systematic review and meta-analysis of randomized controlled trials.
Topics: Aminolevulinic Acid; Cystoscopy; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Photochemot | 2023 |
Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.
Topics: Aminolevulinic Acid; Cost-Benefit Analysis; Cystectomy; Cystoscopy; Disease-Free Survival; Health Ca | 2013 |
Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
Topics: Aminolevulinic Acid; Cost-Benefit Analysis; Cystectomy; Cystoscopy; Disease Progression; Disease-Fre | 2014 |
5-Aminolevulinic Acid-Protoporphyrin IX Fluorescence-Guided Surgery of High-Grade Gliomas: A Systematic Review.
Topics: Aminolevulinic Acid; Brain; Brain Neoplasms; Fluorescence; Glioblastoma; Humans; Microscopy, Fluores | 2016 |
Fluorescence-guided resection of malignant gliomas using 5-aminolevulinic acid: practical use, risks, and pitfalls.
Topics: Aminolevulinic Acid; Brain; Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Microscopy, F | 2008 |
Fluorescence-guided resection of malignant gliomas using 5-aminolevulinic acid: practical use, risks, and pitfalls.
Topics: Aminolevulinic Acid; Brain; Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Microscopy, F | 2008 |
Fluorescence-guided resection of malignant gliomas using 5-aminolevulinic acid: practical use, risks, and pitfalls.
Topics: Aminolevulinic Acid; Brain; Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Microscopy, F | 2008 |
Fluorescence-guided resection of malignant gliomas using 5-aminolevulinic acid: practical use, risks, and pitfalls.
Topics: Aminolevulinic Acid; Brain; Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Microscopy, F | 2008 |
Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies.
Topics: Aminolevulinic Acid; Cystectomy; Cystoscopy; Disease-Free Survival; Evidence-Based Medicine; Humans; | 2010 |
Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations.
Topics: Aminolevulinic Acid; Cystectomy; Cystoscopy; Disease-Free Survival; Evidence-Based Medicine; Humans; | 2010 |
Glioblastoma multiforme treatment with clinical trials for surgical resection (aminolevulinic acid).
Topics: Aminolevulinic Acid; Brain Neoplasms; Disease-Free Survival; Fluorescent Dyes; Glioblastoma; Humans; | 2012 |
[Surgery of high-grade gliomas guided by fluorescence: a retrospective study of 22 patients].
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; Brain | 2013 |
[Intraoperative photodynamic diagnosis using 5-ALA for glioma surgery].
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioma; Humans; Monitoring, Intraoperative; Neoplasm, Residual | 2005 |
6 trials available for aminolevulinic acid and Minimal Disease, Residual
| Article | Year |
|---|---|
Effects of 5-ALA dose on resection of glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Brain Neoplasms; Contrast Media; Dose-Response | 2019 |
Fractionated illumination improves the outcome in the treatment of precancerous lesions with photodynamic therapy.
Topics: Aminolevulinic Acid; Bowen's Disease; Humans; Keratosis, Actinic; Neoplasm, Residual; Photochemother | 2008 |
Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Austria; Carcinoma, Transitional Cell; Cystosco | 2002 |
Fluorescence-guided resections of malignant gliomas--an overview.
Topics: Aminolevulinic Acid; Biopsy; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Division; Fluorescenc | 2003 |
[Reducing the risk of superficial bladder cancer recurrence with 5-aminolevulinic acid-induced fluorescence diagnosis. Results of a 5-year study].
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Transitional Cell | 2003 |
[Clinical significance of macroscopic 5-aminolevulinic acid (ALA)-inducer fluorescence in transurethral resection of non-invasive bladder cancer].
Topics: Aminolevulinic Acid; Cystectomy; Cystoscopy; Fluorescence; Humans; Light; Neoplasm, Residual; Photos | 2003 |
24 other studies available for aminolevulinic acid and Minimal Disease, Residual
| Article | Year |
|---|---|
Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer.
Topics: Aminolevulinic Acid; Disease Progression; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Ph | 2022 |
5-Aminolevulinic Acid Guided Sampling of Glioblastoma Microenvironments Identifies Pro-Survival Signaling at Infiltrative Margins.
Topics: Adult; Aged; Aminolevulinic Acid; ErbB Receptors; Female; Fluorescence; Glioblastoma; Humans; Male; | 2017 |
Diagnostic accuracy of intraoperative perfusion-weighted MRI and 5-aminolevulinic acid in relation to contrast-enhanced intraoperative MRI and
Topics: Adult; Aged; Aminolevulinic Acid; Brain Neoplasms; Female; Gadolinium DTPA; Glioblastoma; Humans; Ma | 2019 |
Sensitivity of intraoperative 5-aminolevulinic acid fluorescence compared with PET using O-(2-¹⁸F-fluoroethyl)-L-tyrosine to detect cerebral gliomas.
Topics: Aminolevulinic Acid; Brain Neoplasms; Female; Fluorescent Dyes; Glioblastoma; Humans; Male; Monitori | 2013 |
Applicability of dermoscopy for evaluation of patients' response to nonablative therapies for the treatment of superficial basal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Aminoquinolines; Antineoplastic Combined Chemot | 2014 |
Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Brain Neoplasms; Cohort Studies; Disease-Free S | 2014 |
Fluorescence detection of malignant liver tumors using 5-aminolevulinic acid-mediated photodynamic diagnosis: principles, technique, and clinical experience.
Topics: Aged; Aminolevulinic Acid; Anastomotic Leak; Carcinoma, Hepatocellular; Color; Colorectal Neoplasms; | 2014 |
Combination therapy for perianal squamous cell carcinoma in situ with imiquimod and photodynamic therapy.
Topics: Aminolevulinic Acid; Aminoquinolines; Anal Canal; Antineoplastic Agents; Carcinoma, Squamous Cell; C | 2014 |
Combination of Intraoperative Magnetic Resonance Imaging and Intraoperative Fluorescence to Enhance the Resection of Contrast Enhancing Gliomas.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Brain Neoplasms; Female; Glioma; Humans; Intrao | 2015 |
Surgery for Glioblastoma: Impact of the Combined Use of 5-Aminolevulinic Acid and Intraoperative MRI on Extent of Resection and Survival.
Topics: Adult; Aged; Aminolevulinic Acid; Brain Neoplasms; Case-Control Studies; Glioblastoma; Humans; Magne | 2015 |
Diagnostic Accuracy of Hexaminolevulinate in a Cohort of Patients Undergoing Radical Cystectomy.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Transitional Cell | 2017 |
Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carbon Radioisotopes; Cystectomy; Cystoscopy; F | 2009 |
Editorial comment.
Topics: Aminolevulinic Acid; Carbon Radioisotopes; Cystectomy; Cystoscopy; Humans; Neoplasm Recurrence, Loca | 2009 |
Intraoperative tissue fluorescence using 5-aminolevolinic acid (5-ALA) is more sensitive than contrast MRI or amino acid positron emission tomography ((18)F-FET PET) in glioblastoma surgery.
Topics: Adult; Aged; Aminolevulinic Acid; Brain Neoplasms; Contrast Media; Female; Fluorescent Dyes; Gliobla | 2012 |
Fluorescence-guided resection of gliomas.
Topics: Aminolevulinic Acid; Brain Neoplasms; Female; Fluorescence; Glioblastoma; Humans; Magnetic Resonance | 2012 |
Improving the extent of malignant glioma resection by dual intraoperative visualization approach.
Topics: Adult; Aged; Aminolevulinic Acid; Brain; Brain Neoplasms; Female; Fluorescent Dyes; Glioma; Humans; | 2012 |
Increased brain tumor resection using fluorescence image guidance in a preclinical model.
Topics: Aminolevulinic Acid; Animals; Brain Neoplasms; Glioma; Microscopy; Models, Animal; Neoplasm, Residua | 2004 |
Possibility of using laser spectroscopy for the intraoperative detection of nonfluorescing brain tumors and the boundaries of brain tumor infiltrates. Technical note.
Topics: Adult; Aminolevulinic Acid; Astrocytoma; Brain; Brain Neoplasms; Female; Humans; Lasers; Male; Middl | 2006 |
[Photodynamic diagnosis of urothelial neoplasms after intravesicular instillation of 5-aminolevulinic acid].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy; Carcinoma | 1994 |
Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence.
Topics: Aged; Aminolevulinic Acid; Brain Neoplasms; Female; Fluorescence; Fluorometry; Glioma; Humans; Intra | 1998 |
[Fluorescent endoscopy superior to white light endoscopy. Detecting cancers of the urinary bladder earlier].
Topics: Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Transitional Cell; Cystoscopy; Fluorescence; Huma | 2002 |
Flow Cytometry-Based Photodynamic Diagnosis with 5-Aminolevulinic Acid for the Detection of Minimal Residual Disease in Multiple Myeloma.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Flow Cytometry; gamma-Aminobutyric Acid; Humans; Leukocytes; | 2019 |
5-Aminolevulinic Acid and Contrast-Enhanced Ultrasound: The Combination of the Two Techniques to Optimize the Extent of Resection in Glioblastoma Surgery.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Brain Neoplasms; Contrast Media; Female; Follow | 2020 |
Analysis of the surgical benefits of 5-ALA-induced fluorescence in intracranial meningiomas: experience in 204 meningiomas.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Brain Neoplasms; Female; Fluorescence; Humans; | 2016 |